CTOs on the Move

GTC Biotherapeutics, Inc.

www.gtc-bio.com

 
GTC Biotherapeutics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.gtc-bio.com
  • 175 Crossing Blvd Ste 410
    Framingham, MA USA '01702
  • Phone: 508.620.9700

Executives

Name Title Contact Details

Similar Companies

Verinetics

Verinetics is a company that provides the DispenSecur solution for Opioid Medication Management, which offers better control for controlled substances and integrates into existing pharmacy and patient management practices.

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.

netpharmaworld

netpharmaworld is a Addison, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quincy Bioscience

Quincy Bioscience, LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.